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Mitochondrial dysfunction is characteristic of many neurodegenerative diseases. The Parkinson’s disease-
associated ubiquitin–protein ligase, Parkin, is important in the elimination of damaged mitochondria by
autophagy (mitophagy) in a multistep process. Here, we show that a Parkin RING domain mutant (C289G)
fails to redistribute to damaged mitochondria and cannot induce mitophagy after treatment with the mito-
chondrial uncoupler carbonyl cyanide m-methylhydrazone, because of protein misfolding and aggregation.
Parkin(C289G) aggregation and inclusion formation were suppressed by the neuronal DnaJ/Hsp40 chaperone
HSJ1a(DNAJB2a). Importantly, HSJ1a and DNAJB6 also restored mitophagy by promoting the relocation of
Parkin(C289G) and the autophagy marker LC3 to depolarized mitochondria. The rescue of Parkin activity
and suppression of aggregation were J domain dependent for HSJ1a, suggesting the involvement of
Hsp70 in these processes, but were not dependent on the HSJ1a ubiquitin interaction motif. HSJ1a
expression did not enhance mitophagy mediated by wild-type Parkin. These data show the potential of mol-
ecular chaperones to mediate the functional recovery of Parkin misfolding mutants and to combat deﬁcits
associated with Parkin aggregation in Parkinson’s disease.
INTRODUCTION
Parkinson’s disease is the most common neurodegenerative
movement disorder. It is characterized clinically by bradykine-
sia, resting tremor, rigidity and postural instability. Its patho-
logical features include the progressive degeneration of
dopaminergic neurons in the midbrain substantia nigra pars
compacta and the formation of intracytoplasmic inclusions
called Lewy bodies. Most cases of Parkinson’s disease are
sporadic, although several genes have been associated with
familial Parkinson’s disease. Mutations in PARK2, the gene
encoding the protein Parkin, were linked to autosomal reces-
sive juvenile onset Parkinsonism (1). Structurally, Parkin con-
tains an N-terminal ubiquitin-like domain (Ubl) and two
C-terminal RING domains. It functions as a ubiquitin–
protein ligase (2–4) and has been implicated in the formation
of Lewy bodies (5).
Recent evidence suggests that Parkin is involved in
mitochondrial dynamics. This activity may relate to its neuro-
protective functions as it reduces cytochrome c release
from damaged mitochondria, thereby preventing subsequent
induction of the apoptotic cascade (6). Parkin knockout ﬂies
have a reduced lifespan, locomotor deﬁcits, male sterility,
mitochondrial defects and increased oxidative stress (7).
Mutations in PTEN-induced putative kinase 1 (PINK1)
cause autosomal recessive familial Parkinsonism (PARK6),
and PINK1 is a mitochondria-targeted serine–threonine
kinase. PINK1 is also an important regulator of mitochondrial
homeostasis. Interestingly, Parkin and PINK1 knockout ﬂies
have a similar phenotype (8,9), and overexpression of Parkin
can rescue the PINK1 ﬂy knockout phenotype. The phos-
phorylation of Parkin by PINK1 has been suggested to
mediate its relocation to mitochondria (10). A small percen-
tage of Parkin is detected in mitochondrial cristae in prolifer-
ating cells (11), but signiﬁcantly Parkin redistributes to
mitochondria when their mitochondrial membrane potential
is disrupted by uncoupling agents or reactive oxygen species
(12). Moreover, Parkin appears to interact either directly or
indirectly with several proteins that are involved in mitochon-
drial metabolism (13).
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mitochondrial quality control mechanisms. Indeed, the mito-
chondrial morphological abnormalities associated with
Parkin deﬁciency highlight a role for Parkin in mitochondrial
fusion and ﬁssion events (14). Overexpression of dynamin-
related protein 1 (Drp1), which promotes mitochondrial
ﬁssion, rescued the mitochondrial morphological defects in
Parkin-deﬁcient ﬂies (15). Moreover, Parkin overexpression
can protect against deleterious mtDNA mutations (16). Mito-
chondrial ﬁssion is required for the selective degradation of
depolarized mitochondria by autophagy (mitophagy) (17).
Interestingly, a function for Parkin in mitophagy has also
been described (12). This function appears to be a multistep
process that involves PINK1. Initially, PINK1 is stabilized
by mitochondrial depolarization, and the kinase activity of
PINK1, either directly or indirectly, leads to the recruitment
of Parkin to mitochondria. Parkin then stimulates the peri-
nuclear accumulation of mitochondria, via a microtubule-
dependent mechanism, before the recruitment of LC3 and
the remaining autophagic machinery to stimulate mitochon-
drial degradation (18–23).
Pathogenic Parkin mutants have been useful in delineating
these steps. For example, some mutants are competent for
recruitment to depolarized mitochondria, but are unable to
stimulate the degradation of damaged mitochondria (19–23).
The propensity of some disease-related Parkin mutants to
misfold and aggregate into insoluble inclusion bodies,
however, has made it difﬁcult to discriminate between resi-
dues that are essential for these functions and those that are
only important for correct folding. For example, RING1
domain mutants appear to be the most prone to misfolding
and aggregation (24,25). Conserved cysteine residues in
Parkin’s RING domains provide structural stability to the
protein (26), explaining the higher misfolding propensity of
these mutants. However, mutations located outside of the
RING ﬁngers can also reduce the solubility of Parkin and
lead to its aggregation into inclusion bodies (27–31).
Molecular chaperones are important for facilitating correct
protein folding, the cellular response to protein misfolding
and the degradation of misfolded proteins (32). Members of
the Hsp70 family of molecular chaperones participate in the
folding and assembly of newly synthesized proteins, aggrega-
tion prevention, dissolution and refolding of aggregated pro-
teins, translocation of proteins across membranes, clathrin
uncoating and protein degradation (33). Hsp70 activity is
regulated by co-chaperones of the Hsp40/DnaJ family that
stimulate ATP hydrolysis and substrate binding (34). The
neuronal DnaJ/Hsp40-like chaperone HSJ1(DnaJB2) com-
bines an N-terminal J domain through which it regulates
Hsp70 activity and two C-terminal ubiquitin interaction
motifs (UIMs) to promote the sorting of ubiquitylated sub-
strate proteins to the proteasome for degradation (35). The
smaller cytoplasmic and nuclear isoform HSJ1a reduced
protein aggregation and inclusion body formation in models
of polyglutamine expansion diseases (35–37).
The aim of this study was to test the hypothesis that
expression of HSJ1a could inhibit the aggregation of mutant
Parkin and provide proof of concept that molecular chaperones
can functionally rescue a Parkin misfolding mutant for
mitophagy.
RESULTS
The Parkin misfolding mutant C289G is defective
for mitophagy
The expression of wild-type Parkin [FLAG-Parkin(WT)] and
the disease-related Parkin mutants FLAG-Parkin(R42P) and
FLAG-Parkin(C289G) were compared in SK-N-SH neuroblas-
toma cells. SK-N-SH cells express low levels of endogenous
Parkin compared with SH-SY-5Y cells, and transient transfec-
tion increased the level of Parkin dramatically (Supplementary
Material, Fig. S1). Immunocytochemistry revealed that Par-
kin(WT) localized predominantly to the cytoplasm of cells
(Fig. 1). In a minority (5%) of cells, FLAG-Parkin(WT)
formed small cytoplasmic inclusions (Fig. 1A and B).
The FLAG-Parkin(R42P) mutant, which carries a mutation
in Parkin’s Ubl domain, was expressed at levels similar to
Parkin(WT), but showed a tendency to misfold. Indeed,
Parkin(R42P) aggregated into multiple small perinuclear
inclusions in approximately 22% of cells (P , 0.05 compared
with WT) and more was present in the pellet fraction (Sup-
plementary Material, Fig. S1B). In contrast, the RING1
domain mutant FLAG-Parkin(C289G) was expressed at
slightly lower levels than Parkin(WT) and was strongly
aggregation-prone (Fig. 1 and Supplementary Material,
Fig. S1B). A larger proportion was detergent-insoluble and
formed multiple large inclusions throughout the cytoplasm
and nucleus in approximately 86% of cells (P , 0.001 com-
pared with WT). To conﬁrm that the Parkin(C289G)
inclusions were aggregates of misfolded protein,
myc-ubiquitin or GFP-Hsp70 and FLAG-Parkin(C289G)
were transfected into SK-N-SH cells (Supplementary Material,
Fig. S2). Cytoplasmic and nuclear FLAG-Parkin(C289G)
inclusions were decorated with ubiquitin and Hsp70.
Moreover, all Parkin inclusions were positive for ubiquitin
or Hsp70. These ﬁndings suggest that ubiquitin and Hsp70
associate with the mutant Parkin and that FLAG-
Parkin(C289G) is probably misfolded and aggregated.
Based on the ﬁndings described earlier, we tested whether
these disease-associated Parkin mutants would retain their
ability to induce mitophagy (12). To investigate this hypoth-
esis, SK-N-SH cells were transfected with the mitochondrial
marker MitoDsRed and FLAG-Parkin(WT), FLAG-
Parkin(R42P) or FLAG-Parkin(C289G), before treatment
with the mitochondrial uncoupler carbonyl cyanide m-
chlorophenylhydrazone (CCCP). Mitochondrial dynamics
were assessed over time (Fig. 1, Supplementary Material,
Fig. S3). The incidence of cells with overlapping FLAG-
Parkin(WT) and MitoDsRed staining was quantiﬁed over an
8 h time-course (Fig. 1C and D). Mitochondria appeared
similar in untransfected cells and in MitoDsRed-only trans-
fected cells (data not shown), suggesting that transfection
with a mitochondrial marker did not alter the mitochondrial
morphology. SK-N-SH cells express low levels of endogenous
Parkin (Supplementary Material, Fig. S1A), which enabled us
to investigate the effect of Parkin overexpression on mitochon-
drial dynamics.
In untreated cells, FLAG-Parkin(WT) staining was cyto-
plasmic and did not overlap with the MitoDsRed staining
(Supplementary Material, Fig. S3A and Table S1). However,
after 1 h CCCP treatment, the FLAG-Parkin(WT) staining
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staining (Fig. 1C; Supplementary Material, Fig. S3A and
Table S1). FLAG-Parkin(R42P) was also recruited to
damaged mitochondria (Fig. 1C) as efﬁciently as Parkin(WT)
(Fig. 1D). In contrast, FLAG-Parkin(C289G) staining did not
overlap with the MitoDsRed staining, as it was mainly
observed in distinct intracellular inclusions (5% overlap with
mitochondria after 8 h CCCP treatment) (Fig. 1C and D;
Supplementary Material, Table S2). This suggested that the
Parkin RING1 domain mutant could not redistribute to
damaged mitochondria because of protein misfolding,
whereas Parkin(R42P) was still capable of folding sufﬁciently
to be recruited to mitochondria.
FLAG-Parkin(WT) expression induced the accumulation
of impaired mitochondria to perinuclear clusters (91% of
transfected cells after 6 h of CCCP treatment) (Fig. 1E; Sup-
plementary Material, Fig. S3). Similarly, the Parkin Ubl
domain mutant FLAG-Parkin(R42P) retained its ability to
mediate mitochondrial clustering (100% of transfected cells
after 6 h of CCCP treatment) (Fig. 1E). However, the
RING1 domain mutant FLAG-Parkin(C289G) failed to
stimulate mitochondrial clustering (21% after 6 h of CCCP
treatment) (Fig. 1E). In the absence of overexpressed FLAG-
Parkin, only 10% of the cells had clustered mitochondria
after 8 h of CCCP treatment (Supplementary Material,
Fig. S3B). These results suggest that Parkin misfolding result-
ing from C289G amino acid substitution severely compro-
mises the ability of Parkin to modulate mitochondrial
dynamics.
Impaired mitochondria are degraded by autophagy
(12,17,38). To conﬁrm that Parkin was stimulating autophagy
of impaired mitochondria in SK-N-SH cells, we investigated
whether the autophagy marker GFP-LC3 would co-localize
to damaged mitochondria in FLAG-Parkin(WT)-transfected
Figure 1. Parkin(C289G) misfolds and does not trafﬁc to depolarized mitochondria. (A) SK-N-SH cells were transiently transfected with FLAG-Parkin(WT),
FLAG-Parkin(R42P) or FLAG-Parkin(C289G). Twenty-four hours post-transfection, cells were ﬁxed in methanol and immunostained with mouse monoclonal
anti-FLAG and donkey anti-mouse-Cy2 antibodies. Arrows indicate intracellular inclusions. Scale bar: 10 mm. (B) Quantiﬁcation of inclusion incidence in cells
transfected with wild-type or mutant Parkin. Four groups of more than 100 cells were counted for each condition. Error bars represent standard errors (+ SE).
Asterisks indicate a signiﬁcant difference between wild-type and mutant Parkin (∗P , 0.05 and ∗∗∗P , 0.001). (C) SK-N-SH cells were transfected with
MitoDsRed (red) and FLAG-Parkin(WT), FLAG-Parkin(R42P) or FLAG-Parkin(C289G). Twenty hours post-transfection, cells were treated with CCCP
(20 mM, 4 h) before ﬁxation in paraformaldehyde and methanol. Cells were immunolabeled with anti-FLAG (green). Arrows indicate areas that are magniﬁed
in the inset to show overlap or no overlap between the FLAG-Parkin and mitochondrial staining. Scale bar: 10 mm. (D) The incidence of cells with accumulated
mitochondria was quantiﬁed in cells overexpressing MitoDsRed and FLAG-Parkin(WT) (black), FLAG-Parkin(R42P) (red) or FLAG-Parkin(C289G) (blue) and
treated with CCCP (20 mM, 0–6 h). Error bars: +2 SE, n ¼ 4. (E) Quantiﬁcation of the relocation of Parkin mutants to mitochondria. SK-N-SH cells were
transfected with MitoDsRed and FLAG-Parkin(WT) (black), FLAG-Parkin(R42P) (red) or FLAG-Parkin(C289G) (blue). Twenty-four hours post-transfection,
cells were treated with CCCP (20 mM, 0–8 h). Error bars: +2 SE, n ¼ 4.
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Fig. S3C). CCCP treatment for 4 h did not alter the cyto-
plasmic and nuclear localization of GFP-LC3; however, with
Parkin overexpression, an overlap of GFP-LC3 staining was
observed in the majority of mitochondria [FLAG-Parkin(WT)
58% of cells compared with 1% with no Parkin P , 0.001]
(Supplementary Material, Fig. S3 and Table S3). To test
whether Parkin induces the degradation of damaged mitochon-
dria by autophagy, SK-N-SH cells transfected with FLAG-
Parkin(WT) and GFP-LC3 were treated with CCCP and the
autophagy inhibitor 3-methyladenine (3-MA) for 24 h (Sup-
plementary Material, Fig. S4). Cells were ﬁxed and immuno-
labeled with anti-Hsp60 antibody, as a mitochondrial marker.
Only 30% of transfected cells that were treated with CCCP for
24 h were immunopositive for Hsp60 staining, suggesting that
most cells had lost their mitochondria (Supplementary
Material, Fig. S4). In contrast, treatment with the autophagy
inhibitor 3-MA signiﬁcantly increased the number of cells
with mitochondrial staining (63% compared with 30%, P ,
0.001) (Supplementary Material, Fig. S4). In these cells, mito-
chondria were still clustered around the nucleus. As expected,
following inhibition of PI3-kinase by 3-MA, the GFP-LC3
staining did not overlap with the mitochondrial staining.
These ﬁndings support the hypothesis that Parkin induces
the elimination of impaired mitochondria by autophagy.
To verify that Parkin(C289G) was defective for inducing
mitophagy, SK-N-SH cells transfected with FLAG-
Parkin(C289G) and GFP-LC3 were treated with CCCP and
3-MA for 24 h (Supplementary Material, Fig. S4). Cells
were ﬁxed and immunolabeled with an anti-Hsp60 antibody.
The majority (90%) of transfected cells treated with CCCP
for 24 h were immunopositive for Hsp60, suggesting that
FLAG-Parkin(C289G) failed to induce mitophagy. Treatment
with the autophagy inhibitor 3-MA resulted in a small, but not
statistically signiﬁcant, increase in the percentage of cells that
were immunopositive for Hsp60 staining (97%) (Supplemen-
tary Material, Fig. S4). In addition, cells that were subjected
to 3-MA treatment displayed LC3 accumulation around the
nucleus, which did not overlap with mitochondria. We hypoth-
esized that the accumulation of LC3 around the nucleus may
represent LC3 redistribution to inclusions formed by aggre-
gated mutant Parkin and that these inclusions may have
been labeled by LC3 prior to the 3-MA treatment. Conse-
quently, inhibition of autophagy by 3-MA treatment would
have sustained the accumulation of LC3-decorated mutant
Parkin. To test further the hypothesis that Parkin(C289G)
might be targeted for autophagic degradation, SK-N-SH
cells were transfected with FLAG-Parkin(C289G) and the
autophagy marker mCherry-ATG5 (Supplementary Material,
Fig. S4F). ATG5 was recruited to the inclusions formed by
the mutant Parkin, suggesting that misfolded, aggregated Par-
kin(C289G) may be subject to autophagic, as well as proteaso-
mal (27,39,40), degradation.
HSJ1a reduces misfolding and aggregation
of mutant Parkin
The human neuronal co-chaperone HSJ1a reduces protein
aggregation in polyglutamine expansion models of protein
misfolding diseases (35–37). To test whether HSJ1a would
similarly reduce Parkin inclusion formation, SK-N-SH cells
were co-transfected with FLAG-Parkin(C289G) and myc-
HSJ1a (Fig. 2). As before, most cells overexpressing FLAG-
Parkin(C289G) formed multiple large inclusions throughout
the cytoplasm and nucleus, whereas co-expression of HSJ1a
signiﬁcantly reduced FLAG-Parkin(C289G) inclusion inci-
dence (17% compared with 81%, P , 0.001) (Fig. 2A and
B). Importantly, HSJ1a not only reduced the number of cells
with inclusions, but also affected the number of inclusions
per cell. Indeed, although most cells did not have inclusions,
those that did have an inclusion formed one or two juxtanuc-
lear inclusions (Fig. 2A). In these cells, HSJ1a staining over-
lapped with the Parkin inclusion, suggesting that HSJ1a
recognized misfolded Parkin.
The ability of HSJ1 to reduce inclusion formation in a
model of polyglutamine expansion disease is J and UIM
domain dependent (35). Therefore, we tested whether the
effect of HSJ1a on Parkin inclusions required these domains
(Fig. 2). SK-N-SH cells were transfected with FLAG-
Parkin(C289G) and myc-HSJ1a(H31Q) or myc-HSJ1a
(DUIM). The H31Q mutation within the J domain disrupts
the HSJ1 interaction with Hsp70 and the HSJ1 stimulation
of Hsp70 ATPase activity. The myc-HSJ1a(H31Q) mutant
did not signiﬁcantly reduce the incidence of cells with
Parkin inclusions (83% compared with 81%, not signiﬁcant)
(Fig. 2A and B). The co-localization of myc-HSJ1a(H31Q)
with mutant Parkin was preserved (Fig. 2A). This may
reﬂect that the HSJ1a J domain mutant can still bind to, but
not prevent the aggregation, or facilitate the degradation of
mutant Parkin. In contrast, the myc-HSJ1a(DUIM) mutant sig-
niﬁcantly reduced Parkin(C289G) inclusion incidence (27%
compared with 81%, P , 0.001) and was almost as efﬁcient
as myc-HSJ1a (27% compared with 17%, P , 0.05). Like
wild-type HSJ1a, the HSJ1a(DUIM) mutant reduced the
number and size of inclusions per cell and decorated the
remaining inclusions (Fig. 2A).
A ﬁlter trap assay was performed to test the effect of HSJ1a
on Parkin aggregation (Fig. 2C). FLAG-Parkin(C289G) and
myc-HSJ1a were transfected into SK-N-SH cells. Twenty-four
hours post-transfection, cells were lysed in sodium dodecyl
sulfate (SDS) lysis buffer. Cell lysates were applied onto a cel-
lulose acetate membrane in a dot blot apparatus and analyzed
by immunoblotting with mouse monoclonal anti-Parkin anti-
body. Whereas myc-HSJ1a and myc-HSJ1a(DUIM) reduced
by 75% the amount of insoluble Parkin that was retained on
the cellulose acetate membrane, no reduction was observed
when myc-HSJ1a(H31Q) was co-expressed (Fig. 2C). These
data suggest that a functional J domain, but not the UIM
domain, is required for HSJ1a to reduce Parkin aggregation.
The molecular chaperone HSJ1 functionally rescues
Parkin(C892G) for mitophagy
The lack of a requirement for the HSJ1a UIM domain, which
is important for recognizing and protecting ubiquitin chains as
part of proteasomal targeting (35), suggested that HSJ1a could
be stimulating some refolding of Parkin and not just enhancing
the degradation of the misfolded mutant protein. To test this
hypothesis, we investigated whether HSJ1a could rescue the
relocation of Parkin(C289G) to damaged mitochondria
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FLAG-Parkin(C289G) and myc-HSJ1a(WT). Twenty hours
post-transfection, cells were treated with CCCP for 4 h
before ﬁxation and immunolabeling with mouse monoclonal
anti-FLAG antibody. As described earlier, the RING1
domain mutant FLAG-Parkin(C289G) failed to relocate to
impaired mitochondria and to induce their mitophagy. In
addition, FLAG-Parkin(C289G) formed multiple large cyto-
plasmic and nuclear inclusions. However, co-expression with
myc-HSJ1a(WT) appeared partially to rescue the relocation
of FLAG-Parkin(C289G) to damaged mitochondria. Indeed,
the FLAG-Parkin(C289G) staining overlapped with the
MitoDsRed staining in many cells (37% after 8 h) (Fig. 3B;
Supplementary Material, Table S2), and the staining over-
lapped entire mitochondria.
To investigate further whether the HSJ1a-mediated rescue
of mutant Parkin’s relocation to damaged mitochondria was
dependent on the HSJ1a anti-aggregation activity, SK-N-SH
cells were transiently transfected with MitoDsRed, FLAG-
Parkin(C289G) and myc-HSJ1a(H31Q) or myc-HSJ1a
(DUIM), followed by CCCP treatment (Fig. 3A and B). The
myc-HSJ1a(H31Q) failed to rescue FLAG-Parkin(C289G)
redistribution to damaged mitochondria. Indeed, after 8 h of
CCCP treatment, only 11% of myc-HSJ1a(H31Q)-positive
cells showed relocation of FLAG-Parkin(C289G) to mitochon-
dria, compared with 37% in cells overexpressing myc-
HSJ1a(WT) (Fig. 3B). In contrast, myc-HSJ1a(DUIM)
partially rescued the relocation of mutant Parkin to mitochon-
dria in 19% of transfected cells (Fig. 3B, Supplementary
Material, Table S2).
The ability of HSJ1a to restore Parkin(C289G) relocalization
tomitochondriawasconﬁrmedbyamitochondrialfractionation
assay (Fig. 3C). SK-N-SH cells were transiently transfected
withFLAG-Parkin(C289G)andmyc-HSJ1a(WT).At20 hpost-
transfection, cells were treated with CCCP for 4 h before cell
lysis and differential fractionation into cytosolic and mitochon-
drial fractions. Cell lysates from each condition were resolved
by SDS–polyacrylamide gel electrophoresis (PAGE) and sub-
jected to western blotting with mouse monoclonal anti-FLAG
and mouse monoclonal anti-Hsp60 antibodies. FLAG-
Parkin(C289G) was exclusively detected in the cytosolic frac-
tion. However, upon myc-HSJ1a(WT) co-expression, some of
the FLAG-Parkin(C289G) shifted to the mitochondrial fraction
following CCCP treatment. These data support the hypothesis
Figure 2. HSJ1a reduces the aggregation of Parkin(C289G). (A) SK-N-SH cells were transfected with FLAG-Parkin(C289G) and myc-HSJ1a(WT),
myc-HSJ1a(H31Q) or myc-HSJ1a(DUIM), as indicated. Twenty-four hours post-transfection, cells were ﬁxed in methanol and immunostained with anti-FLAG
(green) and sheep anti-HSJ1 antibodies (red). The upper panel shows a representative image, whereas the middle and lower panels show co-localization of HSJ1a
in a rare inclusion-bearing cells. Arrows indicate inclusions. Scale bar: 10 mm. (B) Quantiﬁcation of the incidence of cells with inclusions in cells overexpressing
FLAG-Parkin(C289G) and myc-HSJ1a, myc-HSJ1a(H31Q) or myc-HSJ1a(DUIM). Error bars: +1 SE, n ¼ 4, ∗∗∗P , 0.001, n/s: not signiﬁcant. (C) Filter trap
showing HSJ1a reduction of mutant Parkin aggregation. SK-N-SH cells were transfected with FLAG-Parkin(C289G) and myc-HSJ1a(WT), myc-HSJ1a(H31Q)
or myc-HSJ1a(DUIM), as indicated. Cells were lysed in 2% SDS 24 h post-transfection. Total cell lysates were diluted in 2% SDS lysis buffer. An aliquot of
100 ml of each cell lysate was loaded onto a cellulose acetate membrane on a dot blot apparatus. Samples were analyzed by immunoblotting with mouse mono-
clonal anti-Parkin and goat anti-mouse-HRP (UD: undiluted; 1/2 and 1/4: dilution factors).
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RING1 domain mutant to impaired mitochondria.
HSJ1a(DNAJB2a) is a member of a subfamily of type II
DnaJ proteins that share C-terminal homology beyond the
J domain (41). Other proteins within this subfamily,
DNAJB6 and DNAJB8, do not share the UIM domain with
HSJ1, but are also potent anti-aggregation chaperones (42).
The levels of DNAJB6 and HSJ1 mRNA transcripts are
increased in Parkinson’s disease brains (43), and DNAJB6 is
a component of Lewy bodies (44). As the UIM domain of
HSJ1 did not appear to be critical, we assessed the ability of
DNAJB6 to restore Parkin(C289G) relocation to damaged
mitochondria. We found that myc-DNAJB6 behaved similar
to the HSJ1a(DUIM) mutant and rescued the redistribution
of Parkin(C289G) in 16% of cells (Fig. 3B).
It remained to be determined whether HSJ1a’s ability to
rescue mutant Parkin relocation to impaired mitochondria
could also restore later steps in the mitophagy pathway. To
test this hypothesis, the incidence of cells with clustered peri-
nuclear mitochondria was quantiﬁed (Fig. 3D). Cells
Figure 3. HSJ1a rescues the relocation of Parkin(C289G) to damaged mitochondria. (A) SK-N-SH cells transfected with the mitochondrial marker MitoDsRed
(red), FLAG-Parkin(WT) (green), FLAG-Parkin(C289G) (green) and myc-HSJ1a(WT), myc-HSJ1a(H31Q), myc-HSJ1a(DUIM) or myc-DNAJB6, as indicated.
Twenty hours post-transfection, cells were treated with CCCP (20 mM, 4 h) before ﬁxation in paraformaldehyde and methanol. Cells were immunolabeled with
anti-FLAG (green). Arrows indicate areas that are magniﬁed in the inset to show overlap or no overlap between FLAG-Parkin and mitochondrial staining. Scale
bar: 10 mm. (B) Quantiﬁcation of the effect of myc-HSJ1a(WT) (red) or myc-HSJ1a(H31Q) (blue), myc-HSJ1a(DUIM) (purple), myc-DNAJB6 (green) or no
chaperone (black) on the relocation of FLAG-Parkin(C289G) to mitochondria. Error bars: +2 SE, n ¼ 4. (C) Cell fractionation assay. SK-N-SH cells were
transiently transfected with FLAG-Parkin(C289G)+myc-HSJ1a(WT), as indicated. Twenty hours post-transfection, cells were treated with CCCP (20 mM,
4 h) before cell lysis. Cell lysates were fractionated into cytosolic and mitochondrial fractions. An aliquot of 20 ml of cell lysates or equivalent fraction was
resolved by SDS–PAGE and western blot analysis was performed with anti-FLAG and anti-Hsp60 antibodies. The position of the molecular size markers
(in kDa) is shown on the right. (D) Quantiﬁcation of the effect of myc-HSJ1a(WT) (red), myc-HSJ1a(H31Q) (blue), myc-HSJ1a(DUIM) (purple), myc-DNAJB6
(green) or no chaperone (black) on the ability to rescue mitochondrial accumulation induced by FLAG-Parkin(C289G). Error bars: +2 SE, n ¼ 4.
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mitochondrial clustering. In contrast, co-expression of
myc-HSJ1a(WT) with FLAG-Parkin(C289G) rescued the
accumulation of damaged mitochondria in up to 26% of trans-
fected cells [compared with 6% in cells overexpressing
FLAG-Parkin(C289G)] (Fig. 3D). The J domain mutant
myc-HSJ1a(H31Q) failed to have an effect, as only 8% of
the cells displayed signs of mitochondrial accumulation
(Fig. 3D). myc-HSJ1a(DUIM) and myc-DNAJB6 had an inter-
mediate effect between HSJ1a and HSJ1a(H31Q), as they
restored mitochondrial clustering in 19 and 17% of cells,
respectively (Fig. 3D). This supports the hypothesis that
HSJ1a’s ability to rescue mutant Parkin relocation to impaired
mitochondria also restores mitochondrial accumulation and
that this effect requires a functional J domain.
To test whether HSJ1a can rescue the later stages of Parkin-
mediated mitophagy for Parkin(C289G), the relocation of
GFP-LC3 to mitochondria was quantiﬁed in cells expressing
FLAG-Parkin(WT), FLAG-Parkin(C289G) and myc-HSJ1a
(WT), which were treated with CCCP for 4 h (Fig. 4A;
Supplementary Material, Table S4). In cells expressing FLAG-
Parkin(WT),theLC3stainingoverlappedwiththemitochondrial
staining (63%). In contrast, cells expressing FLAG-
Parkin(C289G) did not demonstrate any overlap between the
LC3 and mitochondrial staining. However, co-expression of
myc-HSJ1a(WT) with FLAG-Parkin(C289G) signiﬁcantly
increased the incidence of cells with LC3 staining on mitochon-
dria [16% compared with 0% in FLAG-Parkin(C289G)-
expressing cells, P , 0.001]. These ﬁndings suggest that
HSJ1a partially recovers the ability of a Parkin RING1 domain
mutant to induce the redistribution of LC3 to depolarized mito-
chondria.
To verify whether the rescued Parkin RING1 domain
mutant could fully induce the clearance of damaged mitochon-
dria by mitophagy, SK-N-SH cells transfected with FLAG-
Parkin(C289G), myc-HSJ1a(WT) and GFP-LC3 were treated
with CCCP and the autophagy inhibitor 3-MA for 24 h
(Fig. 4C). Cells were ﬁxed and immunolabeled with an
anti-Hsp60 antibody. About 60% of FLAG-Parkin(C289G)-
and myc-HSJ1a(WT)-expressing cells were immunopositive
for Hsp60 staining, suggesting that 40% of cells had lost
their mitochondria [with Parkin(C289G) alone only 10% lost
their mitochondria, Supplementary Material, Fig. S4D]. In
contrast, treatment with the autophagy inhibitor 3-MA signiﬁ-
cantly increased the number of cells with mitochondrial stain-
ing (83% compared with 60%, P , 0.5). These ﬁndings
support the hypothesis that the chaperone-mediated rescued
Parkin(C289G) is fully competent for enhancing mitophagy
of damaged mitochondria.
Preferential co-immunoprecipitation of HSJ1a
and Parkin(C289G)
To conﬁrm that HSJ1a could be acting directly on Parkin, we
investigated whether the proteins could be co-precipitated in a
complex. Reciprocal co-immunoprecipitation showed that a
Figure 4. HSJ1a rescues Parkin(C289G) for mitophagy. (A) SK-N-SH cells co-transfected with FLAG-Parkin(WT) or FLAG-Parkin(C289G), myc-HSJ1a(WT)
and GFP-LC3 (green) were treated with CCCP (20 mM, 4 h) and immunolabeled with anti-Hsp60 (red). (B) The percentage of cells with overlapping GFP-LC3
and MitoDsRed staining was quantiﬁed in cells co-transfected with FLAG-Parkin(WT), FLAG-Parkin(C289G)+myc-HSJ1a(WT) and treated with CCCP
(20 mM, 4 h). Error bars: +2 SE, n ¼ 4, ∗∗∗P , 0.001. (C) Quantiﬁcation of the incidence of transfected cells with mitochondrial staining in cells treated
with CCCP (20 mM, 24 h, left bar), CCCP + 3-MA (10 mM, 24 h, right bar). Error bars: +2 SE, n ¼ 4, ∗P , 0.5.
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tated speciﬁcally in the presence of the other binding partner
(Supplementary Material, Fig. S5A). In contrast, there was
greater binding of Parkin(C289G) to HSJ1a compared with
Parkin(WT) despite lower levels of protein in the input
(Supplementary Material, Fig. S5B). Therefore, HSJ1a can
bind both Parkin(WT) and Parkin(C289G), but binds the
mutant protein preferentially.
HSJ1a does not enhance mitophagy of wild-type Parkin
Based on the ability of HSJ1a to bind Parkin and partially
restore the relocation of a Parkin RING1 domain mutant to
mitochondria, thereby rescuing the enhancement of mito-
phagy, it was hypothesized that HSJ1a may also modulate
the activity of wild-type Parkin in mitophagy. To test this
hypothesis, SK-N-SH cells were transfected with MitoDsRed,
FLAG-Parkin(WT) and myc-HSJ1a(WT) (Supplementary
Material, Fig. S6). Twenty-four hours after transfection, cells
were treated with CCCP for 1 h and immunolabeled with an
anti-FLAG antibody. Co-expression of myc-HSJ1a(WT) with
FLAG-Parkin(WT) did not appear to modulate the relocation
of wild-type Parkin to damaged mitochondria, which clustered
around the nucleus (Supplementary Material, Fig. S6A).
Quantiﬁcation of the effect of HSJ1a co-expression on wild-
type Parkin relocation to damaged mitochondria revealed
that myc-HSJ1a(WT) expression reduced the incidence of
cells with FLAG-Parkin(WT) redistribution to mitochondria
(13% compared with 22% after 1 h), although the effect
was not signiﬁcantly different (Supplementary Material,
Fig. S6B). Furthermore, myc-HSJ1a(WT) expression appeared
initially to delay FLAG-Parkin(WT)-induced mitochondrial
clustering, although no difference was observed after
prolonged CCCP treatment [100% with myc-HSJ1a(WT)
compared with 91% in control cells after 6 h CCCP]
(Supplementary Material, Fig. S6C). These ﬁndings suggest
that HSJ1a overexpression does not affect the function of
wild-type Parkin in mitophagy.
DISCUSSION
The elimination of damaged mitochondria by mitophagy is an
important quality control mechanism. We have conﬁrmed that
the ubiquitin–protein ligase Parkin induces mitophagy by
redistributing to mitochondria after membrane depolarization
with the mitochondrial uncoupler CCCP. Parkin stimulated
the accumulation of impaired mitochondria around the
nucleus, induced the relocation of the autophagy marker
LC3 to damaged mitochondria and thus facilitated their elim-
ination by mitophagy. These ﬁndings are reminiscent of the
ﬁndings of Narendra et al. (12), demonstrating that Parkin
selectively eliminates depolarized mitochondria by mito-
phagy. This role for Parkin in mitochondrial quality control
has also been conﬁrmed by others (18–23). The exact mech-
anism whereby Parkin senses and relocates to damaged mito-
chondria is currently not clear, but appears to be dependent on
PINK1 relocation to, or accumulation in, mitochondria
(22,45). However, ubiquitylation of PINK1 by Parkin, or phos-
phorylation of Parkin by PINK1, per se does not appear to be
required (46). A role for PINK1 in mitochondrial ﬁssion has
also been demonstrated (47). Recently, a study has shown
that Parkin, PINK1 and DJ-1 form a ubiquitin–protein ligase
complex that promotes the catalytic activity of Parkin (48).
Whether this complex is implicated in Parkin-mediated mito-
phagy remains to be determined.
The redistribution of Parkin to mitochondria was inhibited
by the disease-related Parkin(C289G) mutation, which could
not induce mitophagy, in agreement with other studies
(19,22). In contrast, the disease-related Parkin Ubl domain
mutant Parkin(R42P) retained its ability to relocate to, and
induce mitophagy of, damaged mitochondria. These ﬁndings
are supported by previous studies demonstrating that R42P
and other mutants in the Ubl domain are competent for enhan-
cing mitophagy (19,21–23); however, Lee et al. (20) suggested
that the R42P mutant was inactive. The reasons for this
difference are not clear, but may reﬂect an increased tendency
for R42P to misfold and aggregate in some cell systems. In
ourassay,theR42Pmutantwaspronetomisfoldandaggregate,
but not enough to affect signiﬁcantly its ability to recruit to
mitochondria. Therefore, Parkin translocation to mitochondria
is RING1 dependent, but does not require the Ubl domain
(10). We propose that some RING1 domain residues are not
required for the relocation of Parkin to mitochondria per se,
but rather that they are necessary for the correct folding of
Parkin into its ﬁnal functional structure. Indeed, several
studies have shown that Parkin RING domain mutants are
prone to misfold (24,25), possibly reﬂecting the importance of
conserved cysteine residues in Parkin’s RING domain to bind
Zn
2+ and provide structural stability. In contrast, other
mutations in the RING1 domain can result in fully mitophagy-
competent proteins (R256C), partially functional (R275W) or
soluble, but non-functional proteins (T204R) (19), such that
the importance of this domain for Parkin’s role in mitophagy
still needs to be determined. Similarly, the Parkin(R42P)
mutant may cause disease through a distinct, misfolding-
independent mechanism such as disruption of its association
with interacting partners or the proteasome. As we discover
the distinct biochemical and cellular phenotypes associated
with Parkin mutations, it will be interesting to determine
whether these correspond to differences in clinical presentation
and/or disease progression.
Importantly, we have demonstrated that the molecular cha-
perone HSJ1a rescued Parkin(C289G) relocation to mitochon-
dria in a J domain-dependent manner, thereby restoring its
function in mitophagy. In addition, HSJ1a restored the
Parkin(C289G)-induced relocation of LC3 to impaired mito-
chondria. Our results suggest that HSJ1a cooperates with
Hsp70 to promote the folding of mutant Parkin. Previous
studies have shown that HSJ1a can reduce inclusion formation
by enhancing the proteasomal degradation of misfolded sub-
strates, but the chaperone did not appear to promote client
protein refolding (35,37). Therefore, the fate of the misfolded
client protein appears to vary depending on the client and not
on the chaperone network exclusively. The lack of require-
ment for the HSJ1a UIM function in the suppression of
Parkin aggregation would seem to reﬂect a change in HSJ1a
action from a pro-degradation chaperone toward a
pro-folding chaperone. We also tested another Hsp70
co-chaperone, DNAJB6, which is present in Lewy bodies
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(data not shown) and promote Parkin relocalization to
damaged mitochondria. DNAJB6 has a potent anti-
aggregation activity for polyglutamine-expanded proteins,
but like HSJ1a does not promote the folding of heat-denatured
ﬁreﬂy luciferase in cells (42). Whether a pro-folding chaper-
one, like DNAJB1 and Hsp70 (49), would be more efﬁcient
in restoring mutant Parkin activity or whether the anti-
aggregation activity is a prerequisite for this recovery
remains to be tested.
HSJ1a was highly efﬁcient at reducing Parkin(C289G)
aggregation, and this was reﬂected by the recovery of its
ability to localize to uncoupled mitochondria to almost wild-
type levels. However, the later processes in Parkin-mediated
mitophagy, such as mitochondrial accumulation, LC3 recruit-
ment and mitochondrial elimination, were less well restored.
This could be a consequence of the unstable nature of the
mutant RING1 domain even in the refolded mutant protein
or a compromise in the chaperone machinery leading to subop-
timal refolding activity. CCCP treatment depletes cellular
ATP levels, and the HSJ1a-mediated Parkin(C289G) refolding
activity was dependent on the ATPase Hsp70. Therefore, the
reduced rescue observed for later stages in the mitophagy
process could reﬂect a loss of chaperone activity associated
with reduced ATP levels within the cell and suggests that if
ATP-dependent chaperones were not compromised, then the
functional recovery of this Parkin mutant might be even
higher. Interestingly, the optimal restoration of mitochondrial
clustering also appeared to require the HSJ1a UIM domain.
HSJ1 proteins interact with other proteins in ubiquitin-
associated proteasomal targeting via the UIM, and whether
the ubiquitin–protein ligase activity of Parkin has inﬂuenced
its relationship with HSJ1a remains to be determined. HSJ1a
did not affect wild-type Parkin-mediated enhancement of the
elimination of damaged mitochondria. In fact, if anything,
HSJ1a caused a slight delay in mitochondrial clustering by
Parkin, possibly reﬂecting a competition with other pathways
stimulated by HSJ1a. The requirement for the HSJ1a UIM
domain could also reﬂect the need for continued maximal anti-
aggregation chaperone activity to prevent seed formation inhi-
biting Parkin function.
A link between mitochondrial dysfunction and protein
aggregation has been demonstrated in the past. Indeed, oxi-
dative stress reduces Parkin’s solubility, precipitating its inac-
tivation (28,50,51). Furthermore, a transgenic mouse that
expresses a truncated form of Parkin (Q311X) is characterized
by the presence of Parkin aggregates and develops some of the
pathological hallmarks of Parkinson’s disease (52), suggesting
that Parkin aggregation, in addition to loss of Parkin function,
could be a component of Parkinson’s disease. Interestingly,
depletion of the 26S proteasomal activity in the mouse brain
results in the formation of Lewy-body-like inclusions that
contain mitochondria (53). Thus, mitochondrial dysfunction
and protein aggregation may form a positive feedback loop,
in which mitochondrial damage promotes protein misfolding
and vice versa.
In summary, to our knowledge, this is the ﬁrst report
demonstrating the functional rescue of a Parkin RING
domain mutant in mitophagy. These data could have important
implications for the treatment of Parkinson’s disease and
possibly other neurodegenerative diseases, based on reducing
protein aggregation and restoring protein homeostasis.
MATERIALS AND METHODS
Plasmids
The generation of pCMV-myc-HSJ1 wild-type and mutant
constructs was described previously (35,54). The pcDNA3.1-
FLAG-Parkin construct was as described (27). The
MitoDsRed plasmid was purchased from Clontech (Oxford,
UK) and the GFP-LC3 and mCherry-ATG5 constructs from
Addgene (Cambridge, MA, USA). The pCMV-myc-DNAJB6
construct was generated by subcloning an Mrj(DNAJB6)
cDNA insert from the original pTCR-His/Mrj construct (55),
a gift from Dr J. Besharse, into an myc-pCMVtag3b vector.
The myc-ubiquitin construct was a gift from Dr R. Kopito,
and the GFP-Hsp70 construct was obtained from
Dr H. Kampinga.
Cell culture and transfections
SK-N-SH cells were cultured in Dulbecco’s modiﬁed Eagle’s
medium H-12 medium (1:1) with GlutaMAXTM I (Invitrogen,
Paisley, UK), supplemented with 10% (v/v) heat-inactivated
fetal calf serum (Invitrogen), 100 U/ml penicillin and
100 mg/ml streptomycin (Invitrogen). Cells were grown at
378C in 5% (v/v) CO2. Transfections using a constant
amount of plasmid DNA were performed using
LipofectamineTM and PLUSTM reagents (Invitrogen), accord-
ing to the manufacturer’s protocol.
Antibodies and reagents
Mouse monoclonal anti-FLAG (M2), mouse monoclonal
anti-Hsp60 (LK1) and mouse monoclonal anti-c-myc (9E10)
antibodies were obtained from Sigma-Aldrich (Gillingham,
UK). Mouse monoclonal anti-Parkin antibody (Park8) was
purchased from Cell Signalling (Hitchin, UK). Generation of
the sheep polyclonal anti-HSJ1
1–277 antibody has been
described previously (54). Secondary antibodies coupled to
Cy2 or Cy3 were purchased from Jackson Immunoresearch
(Newmarket, UK) and goat anti-mouse antibody coupled to
horseradish peroxidase (HRP) from Pierce (Cramlington,
UK). The drugs CCCP and 3-MA were obtained from
Sigma-Aldrich.
Immunocytochemistry and confocal microscopy
Transfected SK-N-SH cells were ﬁxed after 24 h with 4%
(w/v) paraformaldehyde in phosphate-buffered saline (PBS)
for 5 min at 228C and/or in 100% methanol for 5 min at
2208C and washed with PBS. Cells were incubated in block-
ing solution [3% (w/v) bovine serum albumin and 10% (v/v)
donkey serum (Jackson Immunoresearch) in PBS] for 30 min
at 228C. Cells were immunolabeled with primary antibody
diluted in blocking solution for at least 1 h. Cells were
washed twice in PBS and incubated with secondary antibody
diluted in blocking solution for at least 45 min. Cells were
washed twice with PBS and mounted with ﬂuorescence
24 Human Molecular Genetics, 2011, Vol. 20, No. 1mounting medium (Dako, Ely, UK). Confocal images were
obtained using a Zeiss LSM510 confocal microscope at exci-
tation/emission wavelengths of 488/510 nm for Cy2-coupled
secondary antibodies and GFP, and 543/570 nm for
Cy3-coupled secondary antibodies, DsRed and mCherry.
Images were processed in Adobe Photoshop7.0 and Adobe
Illustrator CS2.
Quantiﬁcation and statistical analysis
Cells were analyzed using a Nikon Eclipse 80i ﬂuorescence
microscope quantiﬁed in four randomly chosen groups com-
prising at least 100 cells. Inclusion incidence was quantiﬁed
by counting the number of transfected cells with inclusions.
The incidence of transfected cells showing Parkin relocation
to mitochondria was deﬁned as cells with distinct
re-localization of Parkin that overlapped with mitochondrial
staining. Mitochondrial accumulation was scored for cells
that had a considerable accumulation of mitochondria
around the nucleus, and mitophagy was assessed by the
absence of detectable mitochondrial marker staining. The
mean, standard deviation and standard error were calculated
and statistical signiﬁcance analyzed using an unpaired two-
sample t-test. All experiments were carried out at least three
times, and the data shown are representative of these, but gen-
erally derive from one experiment. To conﬁrm that subjective
scoring of overlapping stains corresponded with
co-localization of markers, co-localization coefﬁcients were
determined using the JACoP plugin for ImageJ (Supplemen-
tary Material, Tables S1–S4 and Method).
Western blot analysis
Transfected SK-N-SH cells were lysed after 24 h in 1% (v/v)
Triton X-100 in PBS containing 1% (v/v) proteinase inhibitor
cocktail (PIC) (Sigma) for 15 min on ice. Cell lysates were
scraped and sonicated, before centrifugation at 13 000g for
15 min at 48C. The samples were resolved by SDS–PAGE
and detected by western blot analysis with the ECL Plus
reagent kit (GE Healthcare, Bucks, UK).
Fractionation assay
Protein extraction for the isolation of mitochondria was per-
formed using the QproteaomeTM mitochondrial isolation kit
(Cat. No. 37612, Qiagen, Crawley, UK), according to the man-
ufacturer’s protocol.
Filter trap assay
Transfected SK-N-SH cells were washed twice in ice-cold
PBS and treated with trypsin-EDTA for 5 min at 228C. Cells
were centrifuged at 1000g for 10 min at 48C. Pellets were
washed in ice-cold PBS and resuspended in SDS lysis buffer
[10 mM Tris–HCl buffer, pH 8.0, containing 150 mM NaCl
and 2% (w/v) SDS] supplemented with 1% (v/v) PIC. Cell dis-
ruption was completed by sonication. A serial dilution of the
samples was performed in SDS lysis buffer. Undiluted and
diluted samples were loaded onto a 0.2 mm cellulose acetate
membrane and pre-equilibrated with SDS wash buffer
[10 mM Tris–HCl buffer, pH 8.0, containing 150 mM NaCl
and 0.1% (w/v) SDS]. After loading, 0.1% (w/v) SDS wash
buffer was added to each well. Samples were allowed to
ﬂow through the cellulose acetate membrane by gravity for
20 min at 228C. Thereafter, membranes were washed three
times in SDS wash buffer, subjected to a vacuum.
Membranes were immunoblotted as described earlier.
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG online.
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